Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The HER-2/neu oncoprotein is a significant cell surface growth factor receptor that plays a crucial role in the regulation of normal cell division and growth. This protein is primarily expressed on the membranes of certain epithelial cells, where it functions to facilitate communication between cells and promote healthy cellular activities. However, when there is an abnormal increase in the number of HER-2/neu proto-oncogenes within the cell nucleus, it leads to the overproduction of this oncoprotein. This overexpression can result in accelerated cell growth rates and mutations, ultimately contributing to the transformation of normal cells into cancerous cells. To assess the presence and quantity of HER-2/neu oncoprotein, immunohistochemistry methods are employed. These methods utilize specific antibodies that bind to the HER-2/neu protein, followed by a staining process that allows for the visualization and quantification of the oncoprotein on the cell membrane. This evaluation is critical for understanding the potential for malignancy and guiding treatment decisions in oncology.
© Copyright 2026 Coding Ahead. All rights reserved.
The HER-2/neu oncoprotein testing is indicated for the following conditions:
The procedure for testing the HER-2/neu oncoprotein involves several key steps that ensure accurate detection and quantification of the protein.
After the HER-2/neu testing procedure, the tissue samples are typically preserved for further analysis if needed. The results of the immunohistochemistry test are usually reported within a few days, providing essential information regarding the HER-2/neu status of the tumor. This information is vital for oncologists to tailor treatment plans, including the potential use of targeted therapies such as trastuzumab (Herceptin) for patients with HER-2/neu positive breast or gastric cancers. Patients may be monitored for any side effects related to the biopsy procedure, and follow-up appointments are scheduled to discuss the results and subsequent treatment options.
| Short Descr | ONCOPROTEIN HER-2/NEU | Medium Descr | ONCOPROTEIN HER-2/NEU | Long Descr | Oncoprotein; HER-2/neu | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 233 - Laboratory - Chemistry and Hematology |
| 90 | Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2011-01-01 | Changed | Short description changed. |
| 2009-01-01 | Changed | Code description changed |
| 2002-01-01 | Added | First appearance in code book in 2002. |
Get instant expert-level medical coding assistance.